PYC Share Price Performance
Recent PYC News & Updates
No updates
PYC Therapeutics Limited Key Details
Last Reported Earnings
Dec 31, 2024
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- -0.083
- Gross Margin
- 100.00%
- Net Profit Margin
- -192.90%
- Debt/Equity Ratio
- 0%
PYC Therapeutics Limited Competitors
About PYC
- Founded
- 2001
- Employees
- n/a
- CEO
- WebsiteView website
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program which is Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for the treatment of blinding eye disease; PYC-002 a drug program for the treatment of a severe neurodevelopmental disorder; and PYC-003, which is indicated to treat autosomal dominant polycystic kidney disease. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
Australian Market Performance
- 7 Days: -0.2%
- 3 Months: 5.5%
- 1 Year: 8.6%
- Year to Date: 5.1%
In the last week, the market has been flat, with a notable exception in the Materials sector dropping 4.2%. Meanwhile, the market is actually up 8.6% over the past year. Earnings are forecast to grow by 11% annually. Market details ›
This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.
Continue reading